As of 14 Oct 2026, ArtBio has raised $132M across 1 verified round on record; latest: $132 million Series B led by B Capital and Sofinnova Partners, announced 29 Jul 2025.
ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients.
1 source
The release names an unnamed previously investing life-sciences fund alongside the co-leads but does not identify it. Cambridge and Oslo appear in the dateline, not as stated headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $132M | 2025-07-29 | B Capital, Sofinnova Partners | No recent discussion |
1 source [ VERIFIED ] read against 1 source The release names an unnamed previously investing life-sciences fund alongside the co-leads but does not identify it. Cambridge and Oslo appear in the dateline, not as stated headquarters. | ||||